On Sep 21, Gilead Sciences, Inc. (NASDAQ:GILD) announced data from four of its Phase 3 studies: ASTRAL-1, ASTRAL-2, ASTRAL-3 and ASTRAL-4, for the …
Analysts are weighing in on the biotechnology giant Gilead Sciences, Inc. (NASDAQ:GILD) and pharmaceutical company Palatin Technologies, Inc.
William Blair’s healthcare analyst John Sonnier weighed in with a favorable report on Gilead Sciences, Inc. (NASDAQ:GILD), after the company announced positive clinical data featuring the company’s next-generation, …
Gilead Sciences, Inc. (NASDAQ:GILD) announced topline results from four international Phase 3 clinical studies (ASTRAL-1, ASTRAL-2, ASTRAL-3 and ASTRAL-4) evaluating a once-daily, fixed-dose …
After the market close on September 11th, Gilead Sciences, Inc. (NASDAQ:GILD) announced that it had raised $9.
Recently, various executives in the healthcare industry have taken part in insider selling activity for the stocks of Gilead Sciences, Inc. (NASDAQ:GILD), bluebird bio Inc (NASDAQ:BLUE), …
Gilead Sciences, Inc. (NASDAQ:GILD) announced that a Phase 3 study evaluating its investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (200/10 mg and …
Gilead Sciences, Inc. (NASDAQ:GILD) announced detailed results from the AMBITION study (a randomized, double-blind, multicenter study of first-line combination therapy with AMBrIsentan and …
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the company’s Marketing Authorization Application (MAA) for an investigational, once-daily single tablet regimen that combines emtricitabine …
I’ve been saying this all year. Ultimately, Gilead Sciences, Inc.
